Key Insights

Highlights

Success Rate

84% trial completion

Published Results

18 trials with published results (12%)

Research Maturity

63 completed trials (42% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.0%

12 terminated out of 150 trials

Success Rate

84.0%

-2.5% vs benchmark

Late-Stage Pipeline

6%

9 trials in Phase 3/4

Results Transparency

29%

18 of 63 completed with results

Key Signals

18 with results84% success12 terminated

Data Visualizations

Phase Distribution

96Total
Not Applicable (38)
Early P 1 (5)
P 1 (17)
P 2 (27)
P 3 (7)
P 4 (2)

Trial Status

Completed63
Recruiting36
Unknown15
Active Not Recruiting13
Terminated12
Not Yet Recruiting5

Trial Success Rate

84.0%

Benchmark: 86.5%

Based on 63 completed trials

Clinical Trials (150)

Showing 20 of 20 trials
NCT07644013RecruitingPrimary

Prospective Multicenter Registry Study of Multiple System Atrophy in China

NCT05167721Phase 2Active Not RecruitingPrimary

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

NCT07197866Phase 2RecruitingPrimary

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT01799915Recruiting

Natural History Study of Synucleinopathies

NCT06568237Phase 2RecruitingPrimary

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06868628Phase 2RecruitingPrimary

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

NCT01136213Not ApplicableCompletedPrimary

Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study

NCT06706622Phase 3Active Not RecruitingPrimary

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT05526391Phase 2CompletedPrimary

A Study of TAK-341 in Treatment of Multiple System Atrophy

NCT07604883Not Yet Recruiting

Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes

NCT04965922Not ApplicableCompletedPrimary

Quality of Life of Caregivers and Patients Suffering From Multiple System Atrophy

NCT00743561Not ApplicableCompleted

Assessment of Ambulatory Polygraphy in the Detection of Sleep Apnea in Multiple System Atrophy (SAMSA)

NCT05826457Enrolling By Invitation

North American Prodromal Synucleinopathy Consortium Stage 2

NCT05819957Not ApplicableCompletedPrimary

Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their Caregivers

NCT07570212Not ApplicableRecruiting

Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders

NCT01577992Not ApplicableCompleted

Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy

NCT03482297Phase 1Completed

Automated Abdominal Binder for Orthostatic Hypotension

NCT04620382Early Phase 1Completed

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

NCT02429557Phase 1Completed

Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

NCT03648905Active Not Recruiting

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Scroll to load more

Research Network

Activity Timeline